Impact of Remdesivir on the Treatment of COVID-19 During the First Wave in Spain.

ABSTRACT:

Introduction

Spain was one of the most affected countries during the first wave of COVID-19, having the highest mortality rate in Europe. The aim of this retrospective study is to estimate the impact that remdesivir-the first drug for COVID-19 approved in the EU-would have had in the first wave.

Methods

This study simulated the impact that remdesivir could have had on the Spanish National Health System (SNHS) capacity (bed occupancy) and the number of deaths that could have been prevented, based on two scenarios: a real-life scenario (without remdesivir) and an alternative scenario (with remdesivir). It considered the clinical results of the ACTT-1 trial in hospitalized patients with COVID-19 and pneumonia who required supplemental oxygen. The occupancy rates in general ward

SUBMITTER: Soriano A 

PROVIDER: S-EPMC8196270 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature